Braveheart Bio Director David I. Malek Buys Shares, Receives Award

What Happened

• David I. Malek, a director of Braveheart Bio, made an open-market purchase of 4,166 shares on 2026-08-07 at $18.00 per share for a total of $74,988. He was also granted a 30,000-share derivative award on 2026-08-05 (reported as $0 acquisition). The purchase is a direct buy; the award is a derivative grant that vests over time.

Key Details

• Transactions and prices:
  • 2026-08-07: Open market purchase (Code P) — 4,166 shares at $18.00 each, total $74,988.
  • 2026-08-05: Grant/award (Code A, derivative) — 30,000 shares, $0 reported (derivative).
• Vesting/conditions: Footnote F2 states the shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the issuer's next annual meeting, subject to continued service.
• Beneficial ownership note: Footnote F1 disclaims beneficial ownership except to the extent of any pecuniary interest.
• Shares owned after the transactions: Not disclosed in the filing.
• Filing timeliness: Report filed 2026-08-07 for transactions on 2026-08-05 and 2026-08-07; the filing shows no indication of a late report.

Context

• The 30,000-share item is a derivative award (stock option/award) that vests based on continued service and a time condition; it is not an immediate sale or cashless exercise. The open-market purchase is a straightforward buy of common stock and is relatively modest in size (~$75k). This filing is factual reporting of both a small insider purchase and a time-vesting equity grant.